RT Journal Article
SR Electronic
T1 Significant reduction in humoral immunity among healthcare workers and nursing home residents 6 months after COVID-19 BNT162b2 mRNA vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.15.21262067
DO 10.1101/2021.08.15.21262067
A1 Canaday, David H.
A1 Oyebanji, Oladayo A.
A1 Keresztesy, Debbie
A1 Payne, Michael
A1 Wilk, Dennis
A1 Carias, Lenore
A1 Aung, Htin
A1 Denis, Kerri St.
A1 Lam, Evan C.
A1 Rowley, Christopher F.
A1 Berry, Sarah D.
A1 Cameron, Cheryl M.
A1 Cameron, Mark J.
A1 Wilson, Brigid
A1 Balazs, Alejandro B.
A1 King, Christopher L.
A1 Gravenstein, Stefan
YR 2021
UL http://medrxiv.org/content/early/2021/08/18/2021.08.15.21262067.abstract
AB High COVID-19 mortality among nursing home (NH) residents led to their prioritization for SARS-CoV-2 vaccination; most NH residents received BNT162b2 mRNA vaccination under the Emergency Use Authorization due to first to market and its availability. With NH residents’ poor initial vaccine response, the rise of NH breakthrough infections and outbreaks, characterization of the durability of immunity to inform public health policy on the need for boosting is needed. We report on humoral immunity from 2 weeks to 6-months post-vaccination in 120 NH residents and 92 ambulatory healthcare worker controls with and without pre-vaccination SARS-CoV-2 infection. Anti-spike and anti-receptor binding domain (RBD) IgG, and serum neutralization titers, were assessed using a bead-based ELISA method and pseudovirus neutralization assay. Anti-spike, anti-RBD and neutralization levels dropped more than 80% over 6 months’ time in all groups irrespective of prior SARS-CoV-2 infection. At 6 months post-vaccine, 72% of the infection-naive NH residents had neutralization titers at or below the lower limit of detection compared to 16% at 2 weeks after full vaccination. These data demonstrate a significant reduction in levels of antibody in all groups. In particular, those infection-naive NH residents had lower initial post-vaccination humoral immunity immediately and exhibited the greatest declines 6 months later. Healthcare workers, given their younger age and relative good-health, achieved higher initial antibody levels and better maintained them, yet also experienced significant declines in humoral immunity. Based on the rapid spread of the delta variant and reports of vaccine breakthrough in NH and among younger community populations, boosting NH residents may be warranted.Competing Interest StatementPotential conflicts of interest. S. G. and D. H. C. are recipients of investigator-initiated grants to their universities from Pfizer to study pneumococcal vaccines and Sanofi Pasteur and Seqirus to study influenza vaccines. S. G. also does consulting for Seqirus, Sanofi, Merck, Vaxart, Novavax, Vaxart, Novavax and Janssen; has served on the speakers bureaus for Seqirus and Sanofi; and reports personal fees from Pfizer and data and safety monitoring board (DSMB) fees from Longevoron. D. H. C. has done consulting work for Seqirus. S. D. B. reports royalties from Wolters-Kluwer, lecture fees from Harvard, and DSMB membership for a trial of zoledronic acid in Parkinson patients, outside the submitted work. C. L. K. reports grants from the Bill & Melinda Gates Foundation, the National Institutes of Health, and Veterans Health Administration, outside the submitted work.Funding StatementThis work was supported by the National Institutes of Health (grant numbers AI12970903S1, 3U54AG06354602S2, and U01 CA26053901) and Veterans Health Administration.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:New England Independent Review Board (NEIRB) is our IRB of record that reviewed and accepted the study protocol and consent documents. The University Hospitals of Cleveland, their local IRB, then accepted that NEIRB are the IRB of record by reliant review. Both panels accepted the IRB application and approved the study before any subjects were enrolled.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe will evaluate collaboration to provide access to the data.